Long-term opioid prescribing has fallen in the United States over the last decade, but millions of patients still received opioids for 90 days or longer in 2023, according to a new research letter in JAMA led by University of Michigan researchers.

UH Seidman Cancer Center researchers to test a gut microbiome intervention as part of a kidney cancer therapy regimen

Congratulations to Dr. G. Michael Harper on being awarded the 2026 Dennis W. Jahnigen Memorial Award for his work advancing geriatrics education through leadership, mentorship, and innovative program development. He will receive the award at #AGS26. https://bit.ly/47P1shy 

In recent decades, the zebrafish has become one of the most valuable model organisms in scientific research. For a variety of reasons, including their genetic similarities to humans, these tiny tropical fish have helped researchers unlock secrets to diseases ranging from muscular dystrophy to melanoma.

Now, Yale researchers are hoping the zebrafish will do the same for autism spectrum disorder.

In a new study, a research team generated a database of 520 U.S. Food and Drug Administration (FDA)-approved drugs and their effects on basic larval zebrafish behaviors and then used the database to identify drug candidates that reverse disrupted behaviors in zebrafish carrying mutations in autism risk genes.

These drug candidates, the researchers say, might represent targets for people carrying mutations in specific autism risk genes.

“Because autism spectrum disorder is highly clinically and genetically heterogeneous, it is challenging to identify drug candidates and many new drugs under investigation are not effective in clinical trials,” said Ellen J. Hoffman, an associate professor at the Yale Child Study Center at Yale School of Medicine (YSM) and senior author of the new study.

“Our study highlights the importance of stratifying or subgrouping autism risk genes to identify potential drug candidates using a precision medicine-based approach.”

The study appears in the journal Proceedings of the National Academy of Sciences.

EANM has joined as co-organiser of the European Multidisciplinary Congress on Urological Cancers (EMUC26), bringing nuclear medicine expertise to Europe’s leading congress on urological cancers. EMUC26 will take place on November 5-8, 2026, in Brussels, Belgium.